Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Connect Reports Positive Results from Pivotal Trial of its Atopic Dermatitis Therapy

publication date: Oct 4, 2022

Connect Biopharma announced 30% of patients with atopic dermatitis (AD) had “clear” or “almost clear” skin after treatment with the company’s lead candidate, CBP-201. More than 80% of the patients reported a 50% reduction in the Eczema Area and Severity Index. CBP-201 was tested in a pivotal China trial that enrolled patients with moderate-to-severe AD. The candidate is an antibody that targets interleukin-4 receptor alpha to modify Th2 cell activity and treat inflammatory diseases. Connect, a Taicang-San Diego biotech developing T cell-driven therapies to treat inflammatory diseases, said it would use the data to file for China approval. More details....

Stock Symbol: (NSDQ: CNTB)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital